ARCA Awarded Method Patent for Gene Response Testing with Investigational Heart Failure Drug
March 31, 2010
ARCA Awarded Method Patent for Gene Response Testing with Investigational Heart Failure Drug
Patent number 7,678,824, entitled "Methods for Treatment with Bucindolol Based on Genetic Targeting," provides market exclusivity to ARCA for its approach to treating patients with heart failure.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Study Suggests Two-Gene Combo Predicts Spectrum of Response to ARCA's Beta Blocker Gencaro
October 24, 2012 / Pharmacogenomics Reporter - Correlogic Developing 'Second Generation' OvaCheck; Seeks Ruling on Quest, LabCorp Licenses
July 8, 2011 / ProteoMonitor - BG Medicine Partners with Siemens on Automated Version of Galectin-3 Heart Failure Prognostic
January 7, 2011 / ProteoMonitor - Patents, Regulation, Reimbursement: Myriad Reflects on Impact of Key Events on Future Business
November 3, 2010 / Pharmacogenomics Reporter - Ahead of FDA Meeting on LDTs, Test Developers Prep for Increased Oversight, but Greater Clarity
July 7, 2010 / Pharmacogenomics Reporter